Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17858418 | 0.87 | ALDH1A1 (0.52) | ALDH1A1KDM1ASRD5A2SRD5A1KDM4E | |
| Hydrochloric Acid SCHEMBL30596790 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KDM1ASRD5A2SRD5A1KDM4E | |
| SCHEMBL6240295 | 0.84 | NPC1 (0.49) | ALDH1A1KDM4EMAPTL3MBTL1HPGD | |
| SCHEMBL5672576 | 0.84 | KDM1A (0.45) | ALDH1A1KDM1AKDM4EKMT2ATSHR | |
| SCHEMBL484995 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM1ASRD5A2SRD5A1KDM4E | |
| SCHEMBL30809642 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM1ASRD5A2SRD5A1KDM4E | |
| SCHEMBL7474144 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM1ASRD5A2SRD5A1KDM4E | |
| SCHEMBL22930890 | 0.80 | HDAC8 (0.41) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL353767 | 0.80 | PTPRC (0.47) | ALDH1A1SRD5A2SRD5A1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL27838744 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM1ASRD5A2SRD5A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3184112-A1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-SS-D-ARABINOFURANOSYL)CYTOSINE | Fujifilm Corporation (JP) | 2017-06-28 | — | — | EP | disclosed |
| CN-104860826-A | Production of substituted phenylene aromatic diesters | DOW GLOBAL TECHNOLOGIES LLC | 2015-08-26 | — | — | CN | disclosed |
| CN-102741215-B | Production of substituted phenylene aromatic diesters | DOW GLOBAL TECHNOLOGIES INC | 2015-04-29 | — | — | CN | disclosed |
| CN-102741215-A | Production of substituted phenylene aromatic diesters | DOW GLOBAL TECHNOLOGIES INC | 2012-10-17 | — | — | CN | disclosed |
| US-6942980-B1 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities | ALLERGAN, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1535919-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Allergan, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1042313-B1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030219832-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | KLEIN ELLIOTT S (US) | 2003-11-27 | — | — | US | disclosed |
| EP-0931786-B1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6008204-A | ANTIDOTES FOR PREVENTING CERTAIN UNDESIRED SIDE EFFECTS OF RETINOIDS | ALLERGAN SALES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5958954-A | 2,2-DIALKYL-4-ARYL-SUBSTITUTED BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES | ALLERGAN SALES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5952345-A | RETINOID ACID RECEPTOR ANTAGONIST; A DERIVATIVES OF ARYL-SUBSTITUTED AND ARYL (3-OXO-1-PROPENLY)-SUBSTITUTED BENZOPYRAN, BENZOTHIOPYRAN, 1,2-DIHYDROQUINOLINE; PREVENTING TOXICITY OR SIDE EFFECTS CAUSED BY RETINOIDS OR VITAMIN A | ALLERGAN SALES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0931786-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Vision Pharmaceuticals L.P. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5877207-A | SKIN DISORDERS; ANTICARCINOGENIC AGENTS | ALLERGAN SALES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1998058922-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0853610-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan (US) | 1998-07-22 | — | — | EP | disclosed |
| US-5776699-A | MEASURING GENE EXPRESSION | ALLERGAN, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219832-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | RXRA, RARA, RXRG | ALDH1A1 200/4885KDM1A 2558/4885SRD5A2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.